Annual document pursuant to section 10 of the German Securities Prospectus Act (Wertpapierprospektgesetz/WpPG)

Pursuant to section 10 of the German Securities Prospectus Act (WpPG), which entered into force on July 1, 2005, listed companies are obliged to make annually available to the public a document containing information published or made available to the public within the preceding twelve months in order to comply with certain regulations under German corporate and capital market law. This annual document refers to the period of January 1 to December 31, 2011.

Ad hoc Releases (§ 15 WpHG)

09.12.2011

Epigenomics AG Completes U.S. Clinical Validation Study for Colorectal Cancer Blood Test Epi proColon; Provides Update on U.S. Regulatory Plans

PDF 79 KB

10.08.2011

Epigenomics AG Announces Restructuring of U.S. and European Operations

PDF 86 KB

28.06.2011

Epigenomics AG: General Assembly Approves all Proposals including Reduction of Share Capital with vast majority

PDF 71 KB

28.02.2011

Epigenomics AG signs Collaboration Agreement in Colorectal Cancer Blood Testing with QIAGEN N.V.

PDF 12.4 KB

Directors' Dealings (§15a WpHG)

	Owned shares as of December 31, 2011	Stock options as of December 31, 2011	Execised options in 2011
Members of the Executive Board
Geert Walther Nygaard Chief Executive Officer	12,000	77,000	0
Dr. Thomas Taapken Chief Financial Officer	2,000	20,000	0
Members of the Supervisory Board
Ann Clare Kessler	2,800	0	0

Declared Securities Transactions during 2011

Date	Members of the Executive Board	Type	Amount of shares	BAFin
April 08, 2011	Geert Walther Nygaard Chief Executive Officer	Buy	10.000	PDF
September 26, 2011	Dr. Thomas Taapken Chief Financial Officer	Buy	1.000	pdf
September 29, 2011	Dr. Thomas Taapken Chief Financial Officer	Buy	800	pdf